Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intuniv in Children With ADHD (AM vs PM Dosing)
NCT00997984Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2009
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of guanfacine in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Started Nov 2009; status: completed.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00997984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00997984.